Product Description
Lu AE04621, a prodrug of catecholamine, was developed as a D1/D2agonist by Lundbecks neurodegeneration portfolio
Mechanisms of Action: DR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Lundbeck
Company Location: DENMARK G7 00000
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Parkinson's Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 16779A | P1 |
Completed |
Parkinson's Disease |
2016-12-01 |
2019-12-03 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|